Document is current
Any future updates will be listed below
-
Authors
Lee, Derek http://orcid.org/0000-0003-4613-0233
Dunn, Zachary Spencer http://orcid.org/0000-0003-2500-6006
Guo, Wenbin http://orcid.org/0000-0002-3916-0314
Rosenthal, Carl J.
Penn, Natalie E.
Yu, Yanqi http://orcid.org/0000-0002-6969-3752
Zhou, Kuangyi
Li, Zhe
Ma, Feiyang http://orcid.org/0000-0002-6260-0787
Li, Miao
Song, Tsun-Ching
Cen, Xinjian http://orcid.org/0000-0002-1663-1347
Li, Yan-Ruide
Zhou, Jin J.
Pellegrini, Matteo http://orcid.org/0000-0001-9355-9564
Wang, Pin http://orcid.org/0000-0002-4132-105X
Yang, Lili http://orcid.org/0000-0001-6568-0404
-
Funding
Funding for this research was provided by:
California Institute for Regenerative Medicine
- License Information
-
More Information
Article History
Received: 9 February 2023
Accepted: 17 October 2023
First Online: 8 November 2023
Competing interests
: D.L., Z.S.D., and L.Y. are inventors on patents (UC Case No. 2023-043, Title: Enhanced Gamma Delta T Cells for Immunotherapy) related to this work filed by UCLA. Currently, Z.S.D. is employed at Guggenheim Securities, N.E.P. is employed at RTM Law, APC, Z.L. is employed at Allogene, F.M. is employed at Amgen, and Y.Y. is employed at Retro Biosciences. P.W. is a co-founder, stockholder, consultant, and advisory board member of Simnova Bio, TCRCure Biopharma, and Appia Bio. L.Y. is a scientific advisor to AlzChem and Amberstone Biosciences, and a co-founder, stockholder, and advisory board member of Appia Bio. None of the declared companies contributed to or directed any of the research reported in this article. The remaining authors declare no competing interests.
